Heat-treated NHS factor VIII concentrate in the United Kingdom--a preliminary study.
Three patients who have been given intermediate purity NHS heat-treated factor VIII concentrate have been followed prospectively for 7-10 months. None had previously received more than six donor units of blood products containing factor VIII. There were no clinical side effects from concentrate administration, haemostasis was satisfactory and no patient developed clinical or laboratory evidence of hepatitis or HTLV III/LAV infection. Heat treatment resulted in the loss of slightly more than 20% of factor VIII activity but in vivo recovery of factor VIII and half disappearance times were within the expected range.
D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission; D000328:Adult; D017977:Deltaretrovirus / Q000302:isolation & purification; D005169:Factor VIII / Q000009:adverse effects / Q000302:isolation & purification / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy; D006526:Hepatitis C / Q000635:transmission; D006518:Hepatitis Viruses / Q000302:isolation & purification; D006358:Hot Temperature; D006801:Humans; D008297:Male; D006113:United Kingdom
D005169:Factor VIII